AMSTERDAM, July 29 /PRNewswire/ --
- Database Now Offers Early Access to Research From 3000 Journals
Scopus(R), the world's largest abstract and citation database of peer-reviewed literature, today announced that it has added "Articles-in-Press" (AiP), abstracts of accepted research papers published prior to being printed, from journals produced by Karger Medical and Scientific Publishers, and Nature Publishing Group (NPG). In the fall, AiPs from BioMed Central and IEEE will also be available. Scopus (http://www.info.scopus.com) previously offered access to AiPs from Elsevier and Springer that included 2500 titles. This number will now rise to approximately 3000.
Scopus AiP abstracts are citable and precede the final published, printed version by up-to-four months, significantly accelerating the knowledge discovery process for researchers. Researchers will gain access to the full-text by linking from Scopus to the publishers' digital library. This early access provides greater connectivity to the current state of research in a range of fields, as well as a more timely method for evaluating the output of authors and institutions. Since AiPs are posted online either as an accepted manuscript or online publication (according to each publisher's release policy), they may still be subject to changes and/or corrections by the author or publisher. Scopus clearly labels AiPs as such so researchers are aware that an updated abstract will be made available once the papers are in print.
"Pre-print articles are extremely helpful in my work as a practitioner," comments Mark Levy, Senior Clinical Research Fellow for the Allergy & Respiratory Research Group at the University of Edinburgh. "I need to be sure I have access to the latest research that is relevant to my patients' needs and treatment plans."
"Gaining access to the research pipeline can have an enormous impact," explains Niels Weertman, Director Scopus and Scirus. "It can open the door for researchers to new ideas and collaboration partners, speeding the advancement of science and in the medical community it can quite literally be a matter of life and death."
Covering the world's research literature, Scopus is the largest abstract and citation database of peer-reviewed literature and quality Web sources with smart tools to track, analyze and visualize research. Scopus was designed and developed with over 500 users and librarians internationally. Its unique database contains abstracts and references from over 15,000 peer-reviewed journals from 4,000 publishers worldwide, ensuring broad interdisciplinary coverage. In addition, Scopus not only offers users citation information about the articles covered, but also directly integrates Web and patent searches. Direct links to full-text articles, library resources and other applications like reference management software, make Scopus quicker, easier and more comprehensive to use than any other literature research tool. For more information about Scopus please visit http://www.info.scopus.com.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
CONTACT: Malkie Bernheim Padilla Speer Beardsley +1-212-752-8338 ext. 662 firstname.lastname@example.org
CONTACT: Malkie Bernheim, Padilla Speer Beardsley, +1-212-752-8338 ext. 662, email@example.com